Latest news with #MedImpact
Yahoo
2 days ago
- Business
- Yahoo
MedImpact Offers Low Cost, Unbranded Ustekinumab-aekn Biosimilar to Any Specialty Pharmacy in the US
SAN DIEGO, August 18, 2025--(BUSINESS WIRE)--MedImpact Holdings Inc. today announced that it will have access to an unbranded biosimilar ustekinumab-aekn at a significantly lower cost than the reference Stelara® (ustekinumab). The biosimilar, distributed by Anda, an affiliate of Teva Pharmaceuticals USA, Inc., will be available for direct purchase from MedImpact's preferred partner, Birdi, Inc., by any licensed specialty pharmacy. "Today, a drug's cost rises at each step in the supply chain," said Arpit Patel, MedImpact Senior Vice President of Trade Relations and Supply Chain. "We designed our unbranded strategy to bypass these costs to deliver far greater value to pharmacies and payers, and a more affordable treatment option for patients." As specialty drug costs continue to rise and pharmacies continue to close, MedImpact's unbranded biosimilar strategy provides specialty pharmacies with a new sourcing option and access to lower prices. It also gives payers across healthcare—and not just MedImpact clients—greater flexibility, choice, and control over one of their greatest cost drivers. As part of a broader move to reduce the industry's reliance on rebates and enhance price transparency, payers and members will gain access to the low cost at the point of sale. By using an FDA-designated interchangeable biosimilar purchased from Anda, an affiliate of Teva Pharmaceuticals USA, Inc., a company with proven biosimilar expertise, this strategy is expected to drive increased physician prescribing and enhanced patient acceptance, and ultimately deliver meaningful cost savings. "MedImpact's specialty strategy is deeply rooted in the principle that pharmacies, members, and payers should not have to compromise access for affordability, and this strategy delivers on that promise," said Patel. "The unbranded ustekinumab-aekn, an interchangeable biosimilar to the reference drug Stelara®, is the first of many products we will be providing to expand access, drive affordability, and transform the specialty drug market." The unbranded ustekinumab-aekn biosimilar is expected to be available for purchase on January 01, 2026. To learn more about the unbranded ustekinumab-aekn biosimilar, please contact info@ About MedImpact San Diego-based MedImpact Healthcare Systems, Inc. is the nation's largest independent health solutions, technology, and pharmacy benefit management provider. For 35 years, MedImpact has helped commercial and government healthcare payers improve member health, manage benefits, and reduce drug costs. Today, MedImpact serves more than 20 million members and processes more than $40 billion in pharmacy transactions annually. To learn more, visit us online, follow us on LinkedIn, or contact us at info@ View source version on Contacts Jennifer Kroll, jkroll@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
30-07-2025
- Health
- Business Wire
MedImpact Includes MedEmpower Fuel™ Health and Wellness App as a Standard Part of Pharmacy Benefit Services
SAN DIEGO--(BUSINESS WIRE)--MedImpact, the leading independent pharmacy benefit and health solutions company, today announced that MedEmpower Fuel™, its award-winning digital health and wellness platform, is now a standard component of its pharmacy benefit services—available at no cost to clients and members. MedImpact includes MedEmpower Fuel™ #health and #wellness app as a standard part of pharmacy benefit services. Share 'By embedding MedEmpower Fuel as a benefit, MedImpact is looking beyond the prescription to deliver a solution that not only enhances member satisfaction and health outcomes, but also helps payers improve member health and reduce overall healthcare costs,' said Zach Johnson, MedImpact Executive Vice President. 'It's personalized, engaging, and innovative—exactly what's needed to drive sustainable change.' This offering comes at a critical time. The widespread adoption of GLP-1 medications for obesity and diabetes has placed a heavy and growing financial burden on payers. These medications, while effective, come with significant long-term cost implications. If a patient with obesity discontinues treatment—as at least half do within the first year—they typically regain the lost weight, according to the Journal of the American Medical Association (JAMA). The MedEmpower Fuel app empowers individuals to make healthier choices by providing personalized meal planning, activity tracking, and behavioral coaching—all designed to support weight management, chronic disease prevention, and medication adherence. By integrating this app into the pharmacy benefit design, MedImpact aims to reduce long-term healthcare costs by addressing the root causes of high-cost conditions. In addition to the nutrition and wellness platform now a part of MedImpact's core pharmacy benefit, MedEmpower Fuel also offers clinical condition management programs tailored specifically for people with hypertension, cancer, autoimmune disease, and behavioral health challenges with one-on-one coaching. And while these supplemental bundles are available to health plans at an additional cost, they provide personalized clinical support to people with the most complex and costly health challenges. MedEmpower Fuel is one part of MedImpact's enterprise-wide strategy to deliver lower costs and improved access for members, payers, and pharmacies. This includes providing wholesale access to biosimilars to any specialty pharmacy, more flexible and cost-effective formulary choices, and price guarantees, among other features. An independent company with scale, clinical strength, and advanced technology, MedImpact is uniquely able—and driven—to offer this combination of solutions, technology, accountability, and transparency. 'The status quo is just not enough,' continued Johnson. 'MedEmpower Fuel reflects our commitment to innovation, integration, and impact—blending pharmacy, behavioral, and nutritional insights into one seamless experience that supports members where they are.' MedEmpower Fuel is immediately available to MedImpact clients. About MedImpact San Diego-based MedImpact Healthcare Systems, Inc. is the nation's largest independent health solutions, technology, and pharmacy benefit management provider. For 35 years, MedImpact has helped commercial and government healthcare payers improve member health, manage benefits, and reduce drug costs. Today, MedImpact serves more than 20 million members and processes more than $40 billion in pharmacy transactions annually. To learn more, visit us online, follow us on LinkedIn, or contact us at info@
Yahoo
01-07-2025
- Business
- Yahoo
MedImpact Achieves NCQA UM Accreditation Three-Year Renewal
SAN DIEGO, July 01, 2025--(BUSINESS WIRE)--MedImpact, the nation's largest independent pharmacy benefit and health solutions company, announced today that it has earned a three-year reaccreditation in Utilization Management from the National Committee for Quality Assurance (NCQA). This marks MedImpact's fourth consecutive NCQA UM Accreditation. "Achieving NCQA Utilization Management Accreditation demonstrates that MedImpact has the systems, processes, and personnel in place to conduct utilization management in accordance with the strictest quality standards," stated Margaret E. O'Kane, President, NCQA. NCQA is an independent, nonprofit organization dedicated to improving healthcare quality through voluntary, objective, and evidence-based evaluations. NCQA accreditation is a key critical differentiator for pharmacy benefit managers (PBMs) seeking to partner with health plans, managed care organizations, and accountable care organizations. "For more than 35 years, MedImpact has ensured timely access to medications and supported improved health outcomes by putting our clients and members at the center of care," said Denise Burns, Chief Operations Officer at MedImpact. "NCQA represents the gold standard in healthcare quality, and this recognition reflects our continued commitment to clinical excellence, responsible utilization, and delivering connected care that supports both quality and affordability." MedImpact continues to lead the way in clinical innovation, investing heavily in a world-class clinical team, and delivering personalized care solutions. This forward-thinking approach drives effective utilization management, high-touch member engagement, and low year-over-year cost trend. Today, MedImpact supports more than 55 million consumers globally, including many of the nation's most recognizable health plans and self-insured employers. "MedImpact's successful NCQA UM Accreditation renewal and continued URAC PBM Accreditation validate the integrity of our clinical programs and operational excellence, reinforce our commitment to uphold the highest standards of quality and transparency, and reaffirm our position as a trusted healthcare leader," Burns said. NCQA has reviewed and accredited MedImpact's Utilization Management functions only. For complete details on the scope of this review, visit About MedImpact MedImpact Healthcare Systems, Inc., based in San Diego, is the nation's largest independent health solutions, technology, and pharmacy benefit management provider. For 35 years, MedImpact has partnered with commercial and government healthcare payers to improve member health, manage pharmacy benefits, and reduce drug costs. The company serves more than 55 million consumers globally and processes over $40 billion in pharmacy transactions annually. To learn more, visit us online, follow us on LinkedIn, or contact us at info@ About NCQA NCQA is a private, nonprofit organization dedicated to improving health care quality. NCQA accredits and certifies a wide range of health care organizations. It also recognizes clinicians and practices in key areas of performance. NCQA's Healthcare Effectiveness Data and Information Set (HEDIS®) is the most widely used performance measurement tool in healthcare. NCQA's website ( contains information to help consumers, employers and others make more informed health care choices. NCQA can be found online at on X (Twitter) @ncqa, on Facebook at and on LinkedIn at View source version on Contacts Jennifer Krolljkroll@ Sign in to access your portfolio
Business Wire
01-07-2025
- Business
- Business Wire
MedImpact Achieves NCQA UM Accreditation Three-Year Renewal
SAN DIEGO--(BUSINESS WIRE)-- MedImpact, the nation's largest independent pharmacy benefit and health solutions company, announced today that it has earned a three-year reaccreditation in Utilization Management from the National Committee for Quality Assurance (NCQA). This marks MedImpact's fourth consecutive NCQA UM Accreditation. 'Achieving NCQA Utilization Management Accreditation demonstrates that MedImpact has the systems, processes, and personnel in place to conduct utilization management in accordance with the strictest quality standards,' stated Margaret E. O'Kane, President, NCQA. NCQA is an independent, nonprofit organization dedicated to improving healthcare quality through voluntary, objective, and evidence-based evaluations. NCQA accreditation is a key critical differentiator for pharmacy benefit managers (PBMs) seeking to partner with health plans, managed care organizations, and accountable care organizations. 'For more than 35 years, MedImpact has ensured timely access to medications and supported improved health outcomes by putting our clients and members at the center of care,' said Denise Burns, Chief Operations Officer at MedImpact. 'NCQA represents the gold standard in healthcare quality, and this recognition reflects our continued commitment to clinical excellence, responsible utilization, and delivering connected care that supports both quality and affordability.' MedImpact continues to lead the way in clinical innovation, investing heavily in a world-class clinical team, and delivering personalized care solutions. This forward-thinking approach drives effective utilization management, high-touch member engagement, and low year-over-year cost trend. Today, MedImpact supports more than 55 million consumers globally, including many of the nation's most recognizable health plans and self-insured employers. 'MedImpact's successful NCQA UM Accreditation renewal and continued URAC PBM Accreditation validate the integrity of our clinical programs and operational excellence, reinforce our commitment to uphold the highest standards of quality and transparency, and reaffirm our position as a trusted healthcare leader,' Burns said. NCQA has reviewed and accredited MedImpact's Utilization Management functions only. For complete details on the scope of this review, visit About MedImpact MedImpact Healthcare Systems, Inc., based in San Diego, is the nation's largest independent health solutions, technology, and pharmacy benefit management provider. For 35 years, MedImpact has partnered with commercial and government healthcare payers to improve member health, manage pharmacy benefits, and reduce drug costs. The company serves more than 55 million consumers globally and processes over $40 billion in pharmacy transactions annually. To learn more, visit us online, follow us on LinkedIn, or contact us at info@ About NCQA NCQA is a private, nonprofit organization dedicated to improving health care quality. NCQA accredits and certifies a wide range of health care organizations. It also recognizes clinicians and practices in key areas of performance. NCQA's Healthcare Effectiveness Data and Information Set (HEDIS®) is the most widely used performance measurement tool in healthcare. NCQA's website ( contains information to help consumers, employers and others make more informed health care choices. NCQA can be found online at on X (Twitter) @ncqa, on Facebook at and on LinkedIn at
